Company: LENZ
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001815776-25-000056
Chunk: 582

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Part I, Item 2
Chunk 582
---
 share. Some of the factors that may cause the market price of our common stock to fluctuate include: 

•price and volume fluctuations in the overall stock market from time to time; 

•the timing and results of clinical trials for LNZ100 and any future product candidates that we may develop; 

•our ability to obtain regulatory approvals for LNZ100 or any future product candidates that we may develop, and any delays or failures to obtain such approvals;

•commencement or termination of collaborations for our product development and research programs; 

•failure to achieve development, regulatory or commercialization milestones under our collaborations; 

•failure or discontinuation of any of our product development and research programs; 

75

•results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; 

•the level of expenses related to any of our research programs, clinical development programs or product candidates that we may develop; 

•the results of our efforts to develop additional product candidates or products; 

•regulatory actions with respect to our products or those of our competitors; 

•developments or disputes concerning patent applications, issued patents or other proprietary rights; 

•announced or completed acquisitions of businesses, products or intellectual property by us or our competitors; 

•actual or anticipated changes in the financial projections or development timelines we may provide to the public or our failure to meet those projections or timelines; 

•market conditions in the biotechnology, pharmaceutical and ophthalmology sectors; 

•changes in the structure of healthcare payment systems;

•sales of shares of our common stock by us or our stockholders, or expectations that such sales may occur, and the expiration of market stand-off or lock-up agreements; 

•the recruitment or departure of key personnel; 

•the public’s reaction to our press releases, other public announcements, and filings with the SEC; 

•rumors and market speculation involving us or other companies in our industry; 

•fluctuations in the trading volume of our shares or the size of our public float; 

•actual or anticipated changes or fluctuations in our results of operations; 

•actual or anticipated developments in our business, our competitors’ businesses, or changes in the market valuations of similar companies and the competitive landscape generally; 

•changes in the market valuations of similar companies; 

•failure of securities analysts to maintain coverage of us, changes in actual or future expectations of investors or securities analysts, or our failure to meet